{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T19:12:53Z","timestamp":1787339573216,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014865","name":"Rare Diseases Foundation","doi-asserted-by":"publisher","award":["FSMR-070805"],"award-info":[{"award-number":["FSMR-070805"]}],"id":[{"id":"10.13039\/100014865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015760","name":"Inserm Transfert SA","doi-asserted-by":"publisher","award":["MAT-PI-15170-A-03"],"award-info":[{"award-number":["MAT-PI-15170-A-03"]}],"id":[{"id":"10.13039\/501100015760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006342","name":"Association Vaincre la Mucoviscidose","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ymthe.2025.08.045","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:05:03Z","timestamp":1757347503000},"page":"6463-6478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Restoring chloride efflux in cystic fibrosis with TMEM16a antisense oligonucleotides"],"prefix":"10.1016","volume":"33","author":[{"given":"Christie","family":"Mitri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Rousselet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madara","family":"Dias Wickramanayaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Foussigni\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Leblanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoire","family":"Gournet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Sonneville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Corvol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1997-2400","authenticated-orcid":false,"given":"Olivier","family":"Tabary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.08.045_bib1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.08.045_bib2","article-title":"A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy","volume":"13","author":"Zaher","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.ymthe.2025.08.045_bib3","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3390\/cells11121868","article-title":"One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies","volume":"11","author":"Ensinck","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2025.08.045_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00946-2020","article-title":"ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies","volume":"56","author":"Mall","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ymthe.2025.08.045_bib5","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1126\/science.1163518","article-title":"TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity","volume":"322","author":"Caputo","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.08.045_bib6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cell.2008.09.003","article-title":"Expression cloning of TMEM16A as a calcium-activated chloride channel subunit","volume":"134","author":"Schroeder","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.08.045_bib7","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/nature07313","article-title":"TMEM16A confers receptor-activated calcium-dependent chloride conductance","volume":"455","author":"Yang","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.08.045_bib8","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3390\/cells10112867","article-title":"TMEM16A\/ANO1: Current Strategies and Novel Drug Approaches for Cystic Fibrosis","volume":"10","author":"Mitri","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2025.08.045_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.143598","article-title":"Transmembrane protein 16A in the digestive diseases: A review of its physiology, pharmacology, and therapeutic opportunities","volume":"310","author":"Zhang","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ymthe.2025.08.045_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bbrc.2019.03.001","article-title":"Transcriptional activation of ANO1 promotes gastric cancer progression","volume":"512","author":"Zeng","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2025.08.045_bib11","doi-asserted-by":"crossref","first-page":"13026","DOI":"10.1073\/pnas.1900703116","article-title":"TMEM16A controls EGF-induced calcium signaling implicated in pancreatic cancer prognosis","volume":"116","author":"Crott\u00e8s","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.08.045_bib12","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1002\/jcp.26961","article-title":"Downregulation of microRNA-9 reduces inflammatory response and fibroblast proliferation in mice with idiopathic pulmonary fibrosis through the ANO1-mediated TGF-beta-Smad3 pathway","volume":"234","author":"Dai","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ymthe.2025.08.045_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cancergen.2018.12.004","article-title":"Down-regulation of miR-9 promotes epithelial mesenchymal transition via regulating anoctamin-1 (ANO1) in CRC cells","volume":"231\u2013232","author":"Park","year":"2019","journal-title":"Cancer Genet."},{"key":"10.1016\/j.ymthe.2025.08.045_bib14","doi-asserted-by":"crossref","first-page":"29516","DOI":"10.1074\/jbc.M111.335943","article-title":"MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells","volume":"287","author":"Selcuklu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.08.045_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109016","article-title":"A negative Smad2\/miR-9\/ANO1 regulatory loop is responsible for LPS-induced sepsis","volume":"116","author":"Zhen","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymthe.2025.08.045_bib16","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41467-017-00813-z","article-title":"MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology","volume":"8","author":"Sonneville","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.08.045_bib17","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3389\/fphar.2020.01096","article-title":"Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies","volume":"11","author":"Mitri","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.08.045_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155771","article-title":"Ani9, A Novel Potent Small-Molecule ANO1 Inhibitor with Negligible Effect on ANO2","volume":"11","author":"Seo","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.08.045_bib19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: the use of in vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.08.045_bib20","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/j.1460-2075.1995.tb00119.x","article-title":"A mouse model for the cystic fibrosis delta F508 mutation","volume":"14","author":"van Doorninck","year":"1995","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2025.08.045_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/(SICI)1098-2795(200002)55:2<125::AID-MRD1>3.0.CO;2-Q","article-title":"Morphological changes in the vas deferens and expression of the cystic fibrosis transmembrane conductance regulator (CFTR) in control, deltaF508 and knock-out CFTR mice during postnatal life","volume":"55","author":"Reynaert","year":"2000","journal-title":"Mol. Reprod. Dev."},{"key":"10.1016\/j.ymthe.2025.08.045_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199573","article-title":"A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies","volume":"13","author":"McHugh","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.08.045_bib23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199108223250802","article-title":"Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis","volume":"325","author":"Knowles","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.08.045_bib24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2012.11.034","article-title":"Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis","volume":"162","author":"Moss","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymthe.2025.08.045_bib25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jcf.2017.05.003","article-title":"Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice","volume":"16","author":"Crosby","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ymthe.2025.08.045_bib26","article-title":"Animal Models in the Pathophysiology of Cystic Fibrosis","volume":"9","author":"Semaniakou","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.08.045_bib27","doi-asserted-by":"crossref","first-page":"28698","DOI":"10.1074\/jbc.M109.012120","article-title":"Loss of TMEM16A causes a defect in epithelial Ca2+-dependent chloride transport","volume":"284","author":"Ousingsawat","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.08.045_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajpath.2020.10.017","article-title":"Animal and Cell Culture Models for Cystic Fibrosis","volume":"191","author":"McCarron","year":"2021","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2025.08.045_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.08.045_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcf.2024.10.004","article-title":"A phase I study assessing the safety and tolerability of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T","volume":"24","author":"Caraco","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ymthe.2025.08.045_bib31","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00986-2023","article-title":"Randomised, phase 1\/2a trial of ION-827359, an antisense oligonucleotide inhibitor of ENaC","volume":"10","author":"Sutharsan","year":"2024","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.ymthe.2025.08.045_bib32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14348\/molcells.2023.2172","article-title":"Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives","volume":"46","author":"Kim","year":"2023","journal-title":"Mol. Cells"},{"key":"10.1016\/j.ymthe.2025.08.045_bib33","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0068-2024","article-title":"Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy","volume":"33","author":"Milczewska","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.ymthe.2025.08.045_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413196","article-title":"Revisiting CFTR Interactions: Old Partners and New Players","volume":"22","author":"Farinha","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.08.045_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/genes11050546","article-title":"Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease","volume":"11","author":"Strub","year":"2020","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ymthe.2025.08.045_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00261-2020","article-title":"Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype","volume":"57","author":"Declercq","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ymthe.2025.08.045_bib37","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1038\/mt.2011.206","article-title":"Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense","volume":"19","author":"Moschos","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.08.045_bib38","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1093\/nar\/gkq457","article-title":"Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates","volume":"38","author":"Straarup","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.08.045_bib39","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1096\/fba.2020-00035","article-title":"Potentiating TMEM16A does not stimulate airway mucus secretion or bronchial and pulmonary arterial smooth muscle contraction","volume":"2","author":"Danahay","year":"2020","journal-title":"FASEB Bioadv."},{"key":"10.1016\/j.ymthe.2025.08.045_bib40","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1164\/rccm.202004-1214LE","article-title":"Reply to Olschewski et al.: TMEM16A Potentiation: Possible Drawbacks","volume":"202","author":"Danahay","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymthe.2025.08.045_bib41","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201900462","article-title":"TMEM16A chloride channel does not drive mucus production","volume":"2","author":"Simoes","year":"2019","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.ymthe.2025.08.045_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceca.2019.06.004","article-title":"The multifaceted role of TMEM16A in cancer","volume":"82","author":"Crottes","year":"2019","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ymthe.2025.08.045_bib43","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00424-016-1790-0","article-title":"Cellular functions of TMEM16\/anoctamin","volume":"468","author":"Oh","year":"2016","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.ymthe.2025.08.045_bib44","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jcf.2025.01.010","article-title":"Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in adults with cystic fibrosis","volume":"24","author":"Caley","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ymthe.2025.08.045_bib45","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.jcf.2019.08.007","article-title":"Male reproductive health in cystic fibrosis","volume":"18","author":"Yoon","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ymthe.2025.08.045_bib46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.diff.2019.07.004","article-title":"Reproductive tract biology: Of mice and men","volume":"110","author":"Cunha","year":"2019","journal-title":"Differentiation"},{"key":"10.1016\/j.ymthe.2025.08.045_bib47","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.gyobfe.2015.03.009","article-title":"[Congenital bilateral absence of vas deferens: From diagnosis to assisted reproductive techniques - the experience of three centers]","volume":"43","author":"Beauvillard","year":"2015","journal-title":"Gynecol. Obstet. Fertil."},{"key":"10.1016\/j.ymthe.2025.08.045_bib48","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00965-2018","article-title":"Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension","volume":"53","author":"Papp","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ymthe.2025.08.045_bib49","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1113\/jphysiol.2008.164970","article-title":"The cystic fibrosis transmembrane conductance regulator in reproductive health and disease","volume":"587","author":"Chan","year":"2009","journal-title":"J. Physiol."},{"key":"10.1016\/j.ymthe.2025.08.045_bib50","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1164\/rccm.201908-1641OC","article-title":"TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis","volume":"201","author":"Danahay","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymthe.2025.08.045_bib51","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1007\/s004240100642","article-title":"Relationship between IkappaBalpha deficiency, NFkappaB activity and interleukin-8 production in CF human airway epithelial cells","volume":"443","author":"Tabary","year":"2001","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.ymthe.2025.08.045_bib52","first-page":"S291","article-title":"TARGETING MIR-9 AND ANO1: NEW THERAPEUTIC STRATEGY IN CYSTIC FIBROSIS","volume":"52","author":"Sonneville","year":"2017","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ymthe.2025.08.045_bib53","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2018.12.001","article-title":"Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells","volume":"18","author":"Valley","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ymthe.2025.08.045_bib54","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0014-5793(01)02561-3","article-title":"Green fluorescent protein-based halide indicators with improved chloride and iodide affinities","volume":"499","author":"Galietta","year":"2001","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymthe.2025.08.045_bib55","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.cellsig.2005.06.004","article-title":"Calcium-dependent regulation of NF-(kappa)B activation in cystic fibrosis airway epithelial cells","volume":"18","author":"Tabary","year":"2006","journal-title":"Cell. Signal."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625007191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625007191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:51:53Z","timestamp":1778521913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625007191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1525001625007191"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.045","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Restoring chloride efflux in cystic fibrosis with TMEM16a antisense oligonucleotides","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}